Physician profile
Mohammad Q Baig
NPI 1881000958
$1,127.88
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.95 · 2020: $196 · 2021: $617 · 2022: $255 · 2023: $18.10 · 2024: $14.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $32.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $32.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $214.67 | 2020-2022 | |
| Abbvie INC. | $160.56 | 2021-2022 | |
| Gilead Sciences, INC. | $154.60 | 2021-2022 | |
| Pfizer INC. | $80.95 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $63.19 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $59.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $56.20 | 2020-2021 | |
| Amgen INC. | $49.57 | 2020-2021 | |
| Eisai INC. | $37.44 | 2021 | |
| Global Blood Therapeutics, INC. | $28.30 | 2022 | |
| Horizon Therapeutics Plc | $22.52 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.48 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.12 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.10 | 2023 | Lifevest |
| Alexion Pharmaceuticals, INC. | $15.73 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.08 | 2022 | |
| Mylan Specialty L.P. | $14.63 | 2024 | Yupelri |
| Lilly USA, LLC | $13.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.25 | 2021 | |
| Allergan, INC. | $12.67 | 2021 | |
| Novo Nordisk INC | $12.48 | 2020 | |
| Glaxosmithkline, LLC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.